• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Intra-Cellular

Quote
anonymous said:
Think about this drug for a minute. It’s an atypical that has a schizophrenia indication. It has less EPS, at least in the studies. It works on glutamate. It’s a little different. It will compete in a market that’s 97%+ generic. How profitable will it be for the company with the rebates they will have to pay for coverage, and the cost of doing business? What effect will future government regulations have on it, and other brand drugs? Is it really that much better, and will the docs see the amazing superiority of it vs competitors? In rural areas, the CMHC’s will be the targets because a lot of psychs just don’t treat schizophrenia anymore and ship them off, especially in poor areas. The CMHC’s are under tremendous pressure to lower their costs, and their patients are mostly Medicaid.

It is very much possible that this drug will be viewed as just another atypical that’s a little better for schizophrenia, but nobody can get it because of lack of managed care coverage. Time will tell.
Click to expand...

good thoughts above. Here are a few other to consider.
1. Long acting injectables for Schiz are growing and improving compliance

2. MOA and side effect
Profile Look good. Enough to differentiate there

3. Schiz is entry point. Bigger play is BP and MDD. Huge market and unmet needs. MOA and side effect profile could help differentiate

4. Latuda which is a multi billion dollar brand launched with Schiz only. People laughed at Sunovion for
Launching a branded in a generic market. Sunovion is laughing all the way to the bank

lots to consider here. Some good some bad.
Best of luck to all
 




anonymous said:
good thoughts above. Here are a few other to consider.
1. Long acting injectables for Schiz are growing and improving compliance

2. MOA and side effect
Profile Look good. Enough to differentiate there

3. Schiz is entry point. Bigger play is BP and MDD. Huge market and unmet needs. MOA and side effect profile could help differentiate

4. Latuda which is a multi billion dollar brand launched with Schiz only. People laughed at Sunovion for
Launching a branded in a generic market. Sunovion is laughing all the way to the bank

lots to consider here. Some good some bad.
Best of luck to all
Click to expand...


Drug launches are won and lost on Managed Care coverage. I would not expect there to be much coverage here due to the oversaturated generic market it is coming into. It will take a skilled rep to successfully launch this product to get it pulled through. Which I personally am fine with, but this isn’t going to be a joy ride by any means! It will be hard, really hard, but if you succeed, there is usually good money up for grabs during drug launches!
 




anonymous said:
Drug launches are won and lost on Managed Care coverage. I would not expect there to be much coverage here due to the oversaturated generic market it is coming into. It will take a skilled rep to successfully launch this product to get it pulled through. Which I personally am fine with, but this isn’t going to be a joy ride by any means! It will be hard, really hard, but if you succeed, there is usually good money up for grabs during drug launches!
Click to expand...

You haven't launched in the last decade in this space, if you had you would know about 6x8. Only 8 states have policy that dictates smooth sailing on day 1 before there is even patient 1 on product, everyone else has to stack patients and RX to the sky to get traction in the payer world (government backed and commercial)

Exceptions are Alabama, California, Georgia, New York, North Carolina, South Carolina, Tennessee, and Texas
 




Has anyone not taken a look into the CEO? Yes she started the company years ago however she has started and sold companies before. Her goal is to create and sell. Mark my words three to five years she will sell the company or a hostile takeover will happen. Drug is ok but definitely not superior. Read the data online. Nothing too fantastic if you really look into it. Stock prices have fallen tremendously. Company already has a -30% return on assets, -33 % return on equity and -33% return in vested capital...keeps slipping. Any money made will go to the investors ( lots of them) Not a solid company I would want to invest my time in. Be wise and do your homework. Reason I backed away. Plus it’s public company so there goes your chances for true equity in a company
 




anonymous said:
You haven't launched in the last decade in this space, if you had you would know about 6x8. Only 8 states have policy that dictates smooth sailing on day 1 before there is even patient 1 on product, everyone else has to stack patients and RX to the sky to get traction in the payer world (government backed and commercial)

Exceptions are Alabama, California, Georgia, New York, North Carolina, South Carolina, Tennessee, and Texas
Click to expand...

I disagree with the list of states you claim “smooth sailing” in because I have launched in this space in one of these states and it definitely was not smooth sailing.
 












anonymous said:
good thoughts above. Here are a few other to consider.
1. Long acting injectables for Schiz are growing and improving compliance

2. MOA and side effect
Profile Look good. Enough to differentiate there

3. Schiz is entry point. Bigger play is BP and MDD. Huge market and unmet needs. MOA and side effect profile could help differentiate

4. Latuda which is a multi billion dollar brand launched with Schiz only. People laughed at Sunovion for
Launching a branded in a generic market. Sunovion is laughing all the way to the bank

lots to consider here. Some good some bad.
Best of luck to all
Click to expand...

appreciate your insight here. Thanks.
 








anonymous said:
You haven't launched in the last decade in this space, if you had you would know about 6x8. Only 8 states have policy that dictates smooth sailing on day 1 before there is even patient 1 on product, everyone else has to stack patients and RX to the sky to get traction in the payer world (government backed and commercial)

Exceptions are Alabama, California, Georgia, New York, North Carolina, South Carolina, Tennessee, and Texas
Click to expand...

can you share more info on the policy?
 












What the heck is going on with RxSalesPro? First I'm told the positions (plural!) I wanted to interview for are filled. Then, today, all of the rep positions are open again. WTH?
 








RxSalesPros is all gung ho and then I had an interview. Now, my contact over there is completely radio silent. Totally bizarre. I’ve asked for feedback, told him my perspective on the conversation, and still nothing.
 




anonymous said:
RxSalesPros is all gung ho and then I had an interview. Now, my contact over there is completely radio silent. Totally bizarre. I’ve asked for feedback, told him my perspective on the conversation, and still nothing.
Click to expand...
I think they are in a holding pattern for the 2nd wave territories until the mgrs start. Who knows? Nothing really matters until approval either way. Happy Holidays
 




Contingent offers are out for the first wave. Background checks are done. Just waiting on PDUFA. 10 more days. Launch isn’t until April 1. Hang tight. Oh. And cars won’t be finalized until after approval so don’t get your panties in a wad about Camry and Cherokee
 
















Top Bottom
Back
Quote